Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CiVax
- Development stage
- Preclinical
- Lead developer
- Soligenix
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CiVax is a prophylactic vaccine developed as an immunostimulant, primarily targeting infectious diseases such as COVID-19. The vaccine is designed to stimulate the immune system to provide protection against viral infections. It was initially developed by Soligenix and has reached preclinical development status. Preclinical data suggest that when used as a booster in combination with other vaccines (such as adenovirus-based COVID-19 vaccines), CiVax can induce rapid and broad protection against multiple COVID-19 variants[1][10]. The precise antigenic components, formulation details, or specific mechanism of immune activation have not been publicly disclosed.
- Brand names
- CiVax
Beyond the preview
Go deeper on CiVax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CiVax.